We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

The model, Gemini 2.5 Flash, will soon launch in Vertex AI, Google’s AI development platform. The company says it offers “dynamic and controllable” computing, allowing developers to adjust ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

Google has launched Vertex AI Media Studio, a suite of generative tools for creating full videos using only text prompts. The platform leverages powerful models, such as Imagen 3 for images ...

Google is adding a new open source framework for building agents to its AI and machine learning platform Vertex AI, along with other updates to help deploy and maintain these agents. It unveiled ...

Kenya is set to usher in new laws of digital asset regulations with the introduction of the Virtual Asset Service Providers (VASP) Bill, 2025. The legislation, which has been tabled by the country’s ...

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a ...

At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior Vice President of Investor ...

Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO in a combination regimen with ivacaftor for the treatment of ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the company’s CRISPR Therapeutics-partnered gene therapy Casgevy and maintain ...